Is STE a good stock to buy right now?

Based on our 6-factor quantitative model, STERIS plc (STE) receives a "Reduce" rating with a composite score of 44.1/100. It is ranked #2,779 out of 4,446 stocks. Key factor scores: Quality 44/100, Value 43/100, Momentum 41/100. The timing signal is "Bearish". This is quantitative analysis only — not investment advice.

What is the stock rating for STE?

STERIS plc (STE) has a "Reduce" rating and 2-star score. The composite score of 44.1 ranks it #2,779 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is STE in?

STERIS plc operates in the Healthcare sector (Medical Equipment industry) with a market cap of $21.57 billion. It is classified as a large-cap stock.

Does STE pay a dividend?

Yes, STE pays a dividend with a current yield of 0.95%. For every $1,000 invested, you would receive approximately $9.50 in annual dividend income.

What is STE's P/E ratio?

STE has a trailing P/E ratio of 29.13x. The Healthcare sector average is 23.6x. This P/E is in a moderate range relative to the broader market.

How profitable is STE?

STE's quality factor score is 44/100. Gross margin: 44.4%. ROE: 10.3% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is STE valued compared to peers?

STE's value factor score is 43/100 (higher = cheaper). Key multiples: P/E 29.1x, EV/EBITDA 22.7x. Valuation is roughly in line with peers.

What is STE's debt level?

STE's debt-to-equity ratio is 26%. Sector average: 32%. Low leverage suggests conservative financial management.

STE has a beta of 0.63, meaning it is less volatile than the market. Stability score: 83/100.

Does STE have high short interest?

STE's short interest factor score is 32/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

STE Stock Analysis: Reduce (Score 44.1/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
STE	-0.52%	+1.77%	+0.23%	-12.20%	+2.51%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-0.46%	-1.83%	-0.11%	-11.84%	-27.01%	-	-	-
Alpha vs Sector	+0.83%	+1.43%	+4.04%	-7.37%	-6.69%	-	-	-

Metric	STE	Benchmark
P/E Ratio	29.1x	+23%
EV/EBITDA	22.7x	+258%
Price / Book	3.0x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
STE STERIS plc	44	44	43	41	29.1x	10.3%	44.4%	12.9%	12.6%	26.0x	$21.6B

Key Ratio	TTM	2026	2025	2024	2023	2022	2021	2020	2019	2018
Gross Margin %	0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.4%
Operating Margin %	0.2%	0.2%	0.2%	0.2%	0.1%	0.1%	0.2%	0.2%	0.1%	0.2%
EBITDA Margin %	0.2%	0.2%	0.2%	0.2%	0.1%	0.1%	0.2%	0.2%	0.2%	0.2%
Net Margin %	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%
FCF Margin %	-	-	-	-	-	-	14.5%	12.4%	12.6%	11.2%
ROE %	0.1%	0.0%	0.1%	0.1%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%
ROA %	0.1%	0.0%	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%
ROIC %	0.1%	2.4%	8.0%	7.0%	2.3%	3.5%	8.0%	9.7%	7.8%	7.3%

Key Ratio

TTM

2026

2025

2024

2023

2022

2021

2020

2019

2018

Gross Margin %

0.4%

Operating Margin %

0.2%

0.1%

0.2%

0.1%

0.2%

EBITDA Margin %

0.2%

0.1%

0.2%

Net Margin %

0.1%

0.0%

0.1%

FCF Margin %

14.5%

12.4%

12.6%

11.2%

ROE %

0.1%

0.0%

0.1%

0.0%

0.1%

ROA %

0.1%

0.0%

0.1%

0.0%

0.1%

ROIC %

0.1%

2.4%

8.0%

7.0%

2.3%

3.5%

8.0%

9.7%

7.8%

7.3%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018
	$5.7B	$5.5B	$5.1B	$5.0B	$4.6B	$3.1B	$3.0B	$2.8B	$2.6B
	—	$3.1B	$2.9B	$2.8B	$2.6B	—	—	—	—
	$2.5B	$2.4B	$2.2B	$2.2B	$2.0B	$1.3B	$1.3B	$1.2B	$1.1B
Gross Margin	44.4%	44.0%	43.2%	43.6%	44.0%	43.2%	43.5%	42.2%	41.7%
	—	$1.3B	$1.3B	$1.3B	$1.5B	—	—	—	—
Research & Development	—	$108M	$104M	$102M	$88M	$66M	$66M	$63M	$61M
Depreciation	—	—	—	—	—	$219M	$197M	$226M	$178M
Total Operating Expenses	—	$1.5B	$1.4B	$1.9B	$1.6B	—	—	—	—
	$1.0B	$867M	$836M	$268M	$426M	$548M	$537M	$411M	$400M
EBIT	$1.0B	$867M	$836M	$268M	$426M	$548M	$537M	$411M	$400M
EBITDA	$1.0B	$867M	$836M	$268M	$426M	$774M	$736M	$640M	$584M
Operating Margin	18.0%	15.9%	16.3%	5.4%	9.3%	17.6%	17.7%	14.8%	15.3%
EBITDA Margin	18.0%	15.9%	16.3%	5.4%	9.3%	24.9%	24.3%	23.0%	22.3%
	—	—	$144M	$108M	$90M	$37M	$40M	$45M	$51M
	—	$796M	$703M	$157M	$315M	—	—	—	—
Income Tax Expense	—	$185M	$150M	$52M	$72M	$121M	$91M	$64M	$63M
	$738M	$616M	$380M	$106M	$243M	$397M	$408M	$305M	$292M
Net Margin	12.9%	11.3%	7.4%	2.1%	5.3%	12.8%	13.5%	10.9%	11.1%
	$1.96	$6.24	$3.83	$1.07	$2.50	$4.66	$4.81	$3.59	$3.42
Diluted EPS	$1.96	$6.20	$3.81	$1.07	$2.48	$4.66	$4.81	$3.59	$3.42
Weighted Avg Basic	—	99M	99M	100M	98M	—	—	—	—
Weighted Avg Diluted	—	99M	99M	100M	98M	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

$5.7B

$5.5B

$5.1B

$5.0B

$4.6B

$3.1B

$3.0B

$2.8B

$2.6B

—

$3.1B

$2.9B

$2.8B

$2.6B

—

$2.5B

$2.4B

$2.2B

$2.0B

$1.3B

$1.2B

$1.1B

Gross Margin

44.4%

44.0%

43.2%

43.6%

44.0%

43.2%

43.5%

42.2%

41.7%

—

$1.3B

$1.5B

—

Research & Development

—

$108M

$104M

$102M

$88M

$66M

$63M

$61M

Depreciation

—

$219M

$197M

$226M

$178M

Total Operating Expenses

—

$1.5B

$1.4B

$1.9B

$1.6B

—

$1.0B

$867M

$836M

$268M

$426M

$548M

$537M

$411M

$400M

EBIT

$1.0B

$867M

$836M

$268M

$426M

$548M

$537M

$411M

$400M

EBITDA

$1.0B

$867M

$836M

$268M

$426M

$774M

$736M

$640M

$584M

Operating Margin

18.0%

15.9%

16.3%

5.4%

9.3%

17.6%

17.7%

14.8%

15.3%

EBITDA Margin

18.0%

15.9%

16.3%

5.4%

9.3%

24.9%

24.3%

23.0%

22.3%

—

$144M

$108M

$90M

$37M

$40M

$45M

$51M

—

$796M

$703M

$157M

$315M

—

Income Tax Expense

—

$185M

$150M

$52M

$72M

$121M

$91M

$64M

$63M

$738M

$616M

$380M

$106M

$243M

$397M

$408M

$305M

$292M

Net Margin

12.9%

11.3%

7.4%

2.1%

5.3%

12.8%

13.5%

10.9%

11.1%

$1.96

$6.24

$3.83

$1.07

$2.50

$4.66

$4.81

$3.59

$3.42

Diluted EPS

$1.96

$6.20

$3.81

$1.07

$2.48

$4.66

$4.81

$3.59

$3.42

Weighted Avg Basic

—

99M

100M

98M

—

Weighted Avg Diluted

—

99M

100M

98M

—

STERIS plc (STE) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does STERIS plc Do?

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company was founded in 1985 and is based in Dublin, Ireland. STERIS plc (STE) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Daniel A. Carestio and employs approximately 16,000 people. With a market capitalization of $21.6B, STE is one of the prominent companies in the Healthcare sector.

STERIS plc (STE) Stock Rating — Reduce (April 2026)

As of April 2026, STERIS plc receives a Reduce rating with a composite score of 44.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.STE ranks #2,779 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, STERIS plc ranks #383 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

STE Stock Price and 52-Week Range

STERIS plc (STE) currently trades at $222.31. The stock lost $1.44 (0.6%) in the most recent trading session. The 52-week high for STE is $269.44, which means the stock is currently trading -17.5% from its annual peak. The 52-week low is $204.90, putting the stock 8.5% above its annual trough. Recent trading volume was 147K shares, suggesting relatively thin trading activity.

Is STE Overvalued or Undervalued? — Valuation Analysis

STERIS plc (STE) carries a value factor score of 43/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 29.13x, compared to the Healthcare sector average of 23.63x — a premium of 23%. The price-to-book ratio stands at 3.00x, versus the sector average of 2.75x. The price-to-sales ratio is 3.76x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, STE trades at 22.71x EV/EBITDA, versus 6.34x for the sector.

Overall, STE's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

STERIS plc Profitability — ROE, Margins, and Quality Score

STERIS plc (STE) earns a quality factor score of 44/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 10.3%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 7.0% versus the sector average of -33.1%.

On a margin basis, STERIS plc reports gross margins of 44.4%, compared to 71.5% for the sector. The operating margin is 18.0% (sector: -66.1%). Net profit margin stands at 12.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 12.6% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

STE Debt, Balance Sheet, and Financial Health

STERIS plc has a debt-to-equity ratio of 26.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.48x, indicating strong short-term liquidity. Total debt on the balance sheet is $1.90B.

STE has a beta of 0.63, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for STERIS plc is 83/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.

STERIS plc Revenue and Earnings History — Quarterly Trend

In TTM 2026, STERIS plc reported revenue of $5.72B and earnings per share (EPS) of $1.96. Net income for the quarter was $738M. Gross margin was 44.4%. Operating income came in at $1.03B.

In Q3 2026, STERIS plc reported revenue of $1.50B and earnings per share (EPS) of $1.96. Net income for the quarter was $194M. Gross margin was 43.8%. Revenue grew 9.2% year-over-year compared to Q3 2025. Operating income came in at $273M.

In Q2 2026, STERIS plc reported revenue of $1.46B and earnings per share (EPS) of $1.95. Net income for the quarter was $193M. Gross margin was 44.2%. Revenue grew 9.9% year-over-year compared to Q2 2025. Operating income came in at $266M.

In Q1 2026, STERIS plc reported revenue of $1.39B and earnings per share (EPS) of $1.80. Net income for the quarter was $178M. Gross margin was 45.1%. Revenue grew 8.7% year-over-year compared to Q1 2025. Operating income came in at $246M.

Over the past 8 quarters, STERIS plc has demonstrated a growth trajectory, with revenue expanding from $1.28B to $5.72B. Investors analyzing STE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

STE Dividend Yield and Income Analysis

STERIS plc (STE) currently pays a dividend yield of 0.9%. At this yield, a $10,000 investment in STE stock would generate approximately $$95.00 in annual dividend income. The net margin of 12.9% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

STE Momentum and Technical Analysis Profile

STERIS plc (STE) has a momentum factor score of 41/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 32/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

STE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, STERIS plc (STE) ranks #383 out of 838 stocks based on the Blank Capital composite score. This places STE in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing STE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full STE vs S&P 500 (SPY) comparison to assess how STERIS plc stacks up against the broader market across all factor dimensions.

STE Next Earnings Date

No upcoming earnings date has been announced for STERIS plc (STE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy STE? — Investment Thesis Summary

The quantitative profile for STERIS plc suggests caution. Low volatility (stability score 83/100) reduces downside risk.

In summary, STERIS plc (STE) earns a Reduce rating with a composite score of 44.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on STE stock.

Related Resources for STE Investors

Explore more research and tools: STE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare STE head-to-head with peers: STE vs AZN, STE vs SLGL, STE vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Wealth Enhancement Advisory Services LLC Purchases 5,095 Shares of STERIS plc $STE

STERIS Plc Forms Death Cross, Signaling Potential Bearish Trend Ahead

Mettler-Toledo Posts Q4 Beat and $900 Million FCF Guide: Breaking Down the $1,754 Target

Steris PLC stock outperforms competitors despite losses on the day

Steris extends advisory role for former CFO Michael J. Tokich with reduced salary

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

STERIS plc (STE) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does STERIS plc Do?

STERIS plc (STE) Stock Rating — Reduce (April 2026)

STE Stock Price and 52-Week Range

Is STE Overvalued or Undervalued? — Valuation Analysis

STERIS plc Profitability — ROE, Margins, and Quality Score

STE Debt, Balance Sheet, and Financial Health

STERIS plc Revenue and Earnings History — Quarterly Trend

STE Dividend Yield and Income Analysis

STE Momentum and Technical Analysis Profile

STE vs Competitors — Healthcare Sector Ranking and Peer Comparison

STE Next Earnings Date

Should You Buy STE? — Investment Thesis Summary

Related Resources for STE Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Wealth Enhancement Advisory Services LLC Purchases 5,095 Shares of STERIS plc $STE

STERIS Plc Forms Death Cross, Signaling Potential Bearish Trend Ahead

Mettler-Toledo Posts Q4 Beat and $900 Million FCF Guide: Breaking Down the $1,754 Target

Steris PLC stock outperforms competitors despite losses on the day

Steris extends advisory role for former CFO Michael J. Tokich with reduced salary